S&P 500   3,325.48 (-0.07%)
DOW   27,190.52 (-0.04%)
QQQ   270.78 (-0.10%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
S&P 500   3,325.48 (-0.07%)
DOW   27,190.52 (-0.04%)
QQQ   270.78 (-0.10%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
S&P 500   3,325.48 (-0.07%)
DOW   27,190.52 (-0.04%)
QQQ   270.78 (-0.10%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
S&P 500   3,325.48 (-0.07%)
DOW   27,190.52 (-0.04%)
QQQ   270.78 (-0.10%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
Log in

OTCMKTS:MCUJFMedicure Stock Price, Forecast & News

$0.79
-0.05 (-5.95 %)
(As of 08/6/2020 09:30 AM ET)
Add
Compare
Today's Range
$0.79
Now: $0.79
$0.81
50-Day Range
$0.69
MA: $0.80
$0.85
52-Week Range
$0.69
Now: $0.79
$4.00
Volume4,700 shs
Average Volume860 shs
Market Capitalization$8.42 million
P/E RatioN/A
Dividend YieldN/A
Beta0.26
Medicure Inc., a cardiovascular pharmaceutical company, engages in the research, clinical development, and commercialization of human therapeutics in Canada, the United States, and Barbados. The company primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non ST elevated acute coronary syndrome. The company's products also comprise PREXXARTAN, an oral solution used for the treatment of hypertension. In addition, it is developing TARDOXAL that is in Phase IIa clinical trials for the treatment of tardive dyskinesia/neurological indications; and products for the treatment of acute cardiology. Medicure Inc. was founded in 1997 and is headquartered in Winnipeg, Canada.
Read More
Medicure logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.65 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MCUJF
CUSIPN/A
CIKN/A
Phone204-487-7412

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.20 million
Book Value$1.88 per share

Profitability

Net Income$-14,910,000.00
Net Margins-126.65%

Miscellaneous

EmployeesN/A
Market Cap$8.42 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable
$0.79
-0.05 (-5.95 %)
(As of 08/6/2020 09:30 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MCUJF News and Ratings via Email

Sign-up to receive the latest news and ratings for MCUJF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Medicure (OTCMKTS:MCUJF) Frequently Asked Questions

How has Medicure's stock been impacted by COVID-19 (Coronavirus)?

Medicure's stock was trading at $1.29 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MCUJF stock has decreased by 38.8% and is now trading at $0.79.
View which stocks have been most impacted by Coronavirus
.

When is Medicure's next earnings date?

Medicure is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Medicure
.

How were Medicure's earnings last quarter?

Medicure Inc. (OTCMKTS:MCUJF) issued its earnings results on Tuesday, May, 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.01. The company had revenue of $2.24 million for the quarter. Medicure had a negative return on equity of 33.24% and a negative net margin of 126.65%.
View Medicure's earnings history
.

Has Medicure been receiving favorable news coverage?

Headlines about MCUJF stock have been trending negative on Thursday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Medicure earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Medicure
.

Who are some of Medicure's key competitors?

Who are Medicure's key executives?

Medicure's management team includes the following people:
  • Dr. Albert David Friesen, Founder, Chairman, CEO & Pres (Age 72)
  • Mr. James F. Kinley, CFO & Sec. (Age 41)

What is Medicure's stock symbol?

Medicure trades on the OTCMKTS under the ticker symbol "MCUJF."

How do I buy shares of Medicure?

Shares of MCUJF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medicure's stock price today?

One share of MCUJF stock can currently be purchased for approximately $0.79.

How big of a company is Medicure?

Medicure has a market capitalization of $8.42 million and generates $15.20 million in revenue each year.

What is Medicure's official website?

The official website for Medicure is www.medicure.com.

How can I contact Medicure?

Medicure's mailing address is 2 - 1250 WAVERLEY STREET, WINNIPEG A2, R3T 6C6. The company can be reached via phone at 204-487-7412 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.